New England Law, Boston, JD, 2011
Indian Institute of Science, Bangalore, PhD in Biochemistry, 1992
Guwahati University, Assam, India, BS in Chemistry, 1983
Sanjeev K. Mahanta, PhDAssociate
Sanjeev is a member of the firm’s Intellectual Property and Technology Practice Group. His practice focuses on drafting and prosecuting U.S. and international patent applications. He is also experienced in related matters such as preparing opinions for freedom-to-operate and invalidity, and IP licensing. Sanjeev provides service to both small and large companies and academic institutions.
Sanjeev practices in a wide variety of technology areas including biotechnology, microbiology, immunology, chemistry, materials science, nanotechnology, drug delivery, and diagnostics.
Prior to joining the law profession, Sanjeev was Director of Research in a Biotechnology company focused on developing cancer therapeutics. Previously, Sanjeev had carried out postdoctoral research in molecular biology at Harvard University and at the New York University Medical Center.
News & Media
- Mayo/Alice ‘Directed to’ Inquiry and a Split Federal Circuit: Vanda Pharma v. West-Ward Pharma
- Federal Circuit to Decide if Licensing Agreement Can Prevent Validity Challenge at PTAB
- Issue Preclusion, PTAB, and the Split Federal Circuit: Knowles Electronics v. Cirrus Logic
- USPTO to Clarify Guidance on Written Description of Antibodies
- Reasonable Expectation of Success to the Rescue
- When Post-Filing Evidence to Determine Written Description Support Is Admissible: Amgen v. Sanofi
- Amgen v. Sanofi: A Well Characterized Antigen Insufficient for Written Description of an Antibody
- Idenix v. Gilead: District Court Exercises Discretion to Deny Enhanced Damages
- Federal Circuit Clarifies Standard for Pleading Infringement in Lifetime v. Trim-Lok
- Inquiry into Unexpectedness is Essential Even for Determining Obviousness in Inherency
- Inherency in Obviousness – What is the Correct Standard?